MedPath

The moderating effect of meditation on depressive symptoms and Neuro-immune interaction in depressed college students

Phase 1
Conditions
depressive state
Registration Number
ITMCTR2100005269
Lead Sponsor
Beijing University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Depressed college students (PHQ-9 scale score > 10 points and < 15 points, HAMD scale score > 7 points and < 24 points), the subjects were tested by clinical psychologists from the Psychiatry Department of Beijing Liangxiang Hospital. Scale assessment and enrollment screening;
2. Those who are not required to receive antidepressant treatment in a depressed state;
3. With/without anxiety;
4. Those between the ages of 18 and 30;
5. All research subjects have not used antidepressant drugs within 6 months before the start of the project, and have not taken any drugs related to the treatment of depression during the course of the project until the end of sampling, and have not used any drugs within 1 week before sampling ;
6. Subjects should meet the inclusion criteria for fMRI: right-handed; no claustrophobia; no metal in the body (fillings are allowed);
7. Those who participated voluntarily and signed the informed consent.

Exclusion Criteria

1. Those with organic mental disorder, schizophrenia and bipolar disorder, psychoactive substances and depressive disorders caused by non-addictive substances;
2. Depressed state caused by major life changes or major events;
3. Women who are pregnant or planning to become pregnant and lactating women;
4. Combined with serious primary diseases such as liver, kidney, hematopoietic system and endocrine system;
5. Patients with moderate to severe or severe depression or those who need antidepressant treatment;
6. Those who are seriously ill and require emergency treatment;
7. Those who are paranoid and judged by researchers to be unsuitable for meditation training;
8. Patients who participated in other clinical research projects within 3 months.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
HAMD Depression Scale Score;
Secondary Outcome Measures
NameTimeMethod
Plasma inflammatory factors TNF-a, IL-1ß, IL-6, IFN-?, IL-17 levels in plasma;Brain default mode network resting-state functional connectivity;HAMD Depression Scale Score;Plasma levels of serotonin, dopamine, glutamine and norepinephrine;PHQ-9 Depression Screening Scale Score;Plasma untargeted metabolome assay;Proportion of Th1 lymphocytes and Th17 lymphocytes in peripheral blood;Baker Anxiety Inventory (BAI) Score;
© Copyright 2025. All Rights Reserved by MedPath